Trial · NCT04706429
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Left ventricular mass indexed to body surface area (LVMi) | 12 months | Change in LVMi (g/m2), measured using CMR, from baseline to week 52. |
| Secondary | Urine copper excretion | 12 months | Cumulative urine copper excretion, measured using urinary copper, assessed from baseline to weeks 13, 26, 39 and 52. |
| Secondary | Exercise capacity | 12 months | Change in exercise capacity, measured using cardiopulmonary exercise testing (CPET), assessed from baseline to week 52. |
| Secondary | Number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia | 12 months | Change in number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia, in 24 hours, measured using ambulatory heart monitoring, assessed from baseline to week 52. |
| Secondary | Circulating high sensitivity troponin | 12 months | Change in circulating high sensitivity troponin, assessed from baseline to week 52. |
| Secondary | LV global longitudinal strain, wall thickness, mass, volumes and ejection fraction (EF) | 12 months | Change in LV global longitudinal strain, wall thickness, mass, volumes and ejection fraction (EF) measured using CMR, assessed from baseline to week 52. |
| Secondary | Peak left ventricular outflow | 12 months | Change in peak left ventricular outflow tract gradient, measured using CMR, assessed from baseline to week 52. |
| Secondary | Atrial volume and function | 12 months | Change in atrial volume and function, measured using CMR, assessed from baseline to week 52. |
| Other | LV myocardial cellular mass | 12 months | Change in LV myocardial cellular mass, measured using CMR, from baseline to week 52. |
| Other | LV myocardial extracellular mass | 12 months | Change in LV myocardial extracellular mass, measured using CMR, from baseline to week 52. |
| Other | LV myocardial extracellular volume | 12 months | Change in LV myocardial extracellular volume, measured using CMR, from baseline to week 52. |
| Other | LV late gadolinium enhancement | 12 months | Change in LV late gadolinium enhancement, measured using CMR, from baseline to week 52. |
| Other | PCr/ATP ratio | 12 months | Change in PCr/ATP ratio, measured using 31P MRS (sub-group), from baseline to week 52. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04706429/registered